If they're right, the protein – an enzyme called human aspartyl (asparaginyl) beta-hydroxylase, or HAAH – could ultimately help reduce the number of unnecessary biopsies for prostate cancer and may identify cancer at an earlier stage when treatment would have a higher likelihood of success.
Prostate cancer is expected to account for more than 234,000 new cases and about 27,000 deaths in the United States in 2006. The American Cancer Society recommends that all men over 50 be screened annually with two standard tests: the prostate specific antigen, or PSA, which measures a protein in the blood, and the digital rectal exam, or DRE, which entails a physical exam the prostate.
Yet the PSA and DRE can be inexact and, at times, not specific or sensitive to cancer. High PSA levels are found in both cancerous and healthy tissue, particularly in benign prostate disease, resulting in significant numbers of false positive cases. The DRE, based on physician touch and skill, relies on subjective judgment. As a result, a man who has prostate cancer can have both a normal PSA and DRE. Conversely, an individual with a high PSA and an abnormal DRE could be cancer-free.
"There is a great need for a test that increases the sensitivity and specificity of those two other tests for prostate cancer," said Stephen Keith, M.D., M.S.P.H., president and chief operating officer of Panacea Pharmaceuticals, Inc., Gaithersburg, MD.
Results were presented at the first meeting on Molecular Diagnostics in Cancer Therapeutic Development, organized by the American Association for Cancer Research.
"Currently, if an individual has a high PSA and positive DRE, the recommendation is that he has a biopsy of the prostate, and more often than not – by some estimates, as much as 80 percent of the time – there will not be evidence of cancer," Dr. Keith said.
Yet, biopsies can be painful, expensive and difficult to perform, and may cause a high number of infections, noted Hossein Ghanbari, Ph.D., chief executive officer and chief scientific officer at Panacea.
According to Ghanbari, HAAH is overexpressed in at least 20 types of cancer tested to date, including liver, breast, ovarian, colon, esophageal, and prostate. It has been shown to be involved in tumor growth, invasiveness and cancer spread.
The researchers previously examined tissue from more than 20 different cancer types and compared them to more than 1,000 normal tissue types. Using immunohistochemistry techniques, they found that more than 99 percent of cancers were positive for HAAH. None of the normal issue samples were positive.
To find a more accurate way to detect prostate cancer, Ghanbari and his co-workers at Panacea developed a test in which they could detect HAAH in blood serum.
In the current work, Ghanbari and his co-workers compared HAAH levels in the blood of 16 individuals with prostate cancer to 23 healthy individuals. Those with prostate cancer showed high HAAH levels, whereas none of the normal control individuals did.
"We've learned that HAAH is generally detected in prostate cancer and not in normal prostate tissue, in addition to a number of other cancers," he said.
The scientists foresee the HAAH test used in conjunction with DRE and PSA testing. "We hope our HAAH blood test combined with PSA and DRE will increase the sensitivity and specificity of screening for prostate cancer," said Keith. "Those without cancer can avoid unnecessary biopsies through the use of all three screening tests."
"Having a positive DRE and high PSA, the HAAH would put the final stamp of approval," Ghanbari said.
Panacea scientists are planning clinical trials with prostate tissue samples from 800 patients, including 400 men with prostate cancer and 400 healthy individuals.
"The goal is to be able to take someone with increasing PSA numbers and a positive DRE, measure the HAAH level and look at biopsy results," Ghanbari said, "and be confident that HAAH provides the additional benefit in terms of specificity and sensitivity. The addition of HAAH should improve the prediction of who will have positive biopsy results for prostate cancer."
Warren Froelich | EurekAlert!
What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Materials Sciences
06.12.2016 | Medical Engineering
06.12.2016 | Power and Electrical Engineering